2. Search Result
Search Result
Results for "

convertases

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

6

Peptides

4

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2237
    Boc-Leu-Gly-Arg-AMC

    		Amino Acid Derivatives Endocrinology
    Boc-Leu-Gly-Arg-AMC is a fluorogenic AMC substrate for the convertases. Boc-Leu-Gly-Arg-AMC can be used in enzymatic assays .
    Boc-Leu-Gly-Arg-AMC
  • HY-P5272
    Histatin-3 TFA

    		Bacterial Inflammation/Immunology
    Histatin-3 TFA, a 32 amino acid peptide, possesses powerful antimicrobial properties. Histatin-3 TFA behaves as a substrate for proprotein convertase 1 (PC1), being cleaved by this endoprotease primarily at a site carboxy terminal to the single Arg25 residue (HRGYR decrease SN). Histatin-3 TFA is a moderately potent, reversible and competitive inhibitor of the furin-mediated cleavage of the pentapeptide pGlu-Arg-Thr-Lys-Arg-MCA fluorogenic substrate, with an estimated inhibition constant Ki of 1.98 μM .
    Histatin-3 TFA
  • HY-12402
    SBC-115076
    1 Publications Verification

    		 Ser/Thr Protease Cardiovascular Disease
    SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism .
    SBC-115076
  • HY-118120
    GEMSA

    2-Guanidinoethylmercaptosuccinic acid

    		 Others Neurological Disease
    GEMSA is a potent inhibitor of enkephalin convertase (Ki=8.8 nM). GEMSA elicites analgesia .
    GEMSA
  • HY-153451
    PCSK9-IN-15

    		Ser/Thr Protease Metabolic Disease
    PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .
    PCSK9-IN-15
  • HY-P1028
    Hexa-D-arginine
    3 Publications Verification

    Furin Inhibitor II

    		 Bacterial Infection
    Hexa-D-arginine (Furin Inhibitor II) is a stable furin inhibitor with Ki values 106 nM, 580 nM and 13.2 μM for furin, PACE4 and prohormone convertase-1 (PC1), respectively. Hexa-D-arginine blocks Pseudomonas exotoxin A and anthrax toxins toxicity in vitro and in vivo .
    Hexa-D-arginine
  • HY-153098
    ARC186

    		Complement System Cardiovascular Disease Inflammation/Immunology
    ARC186, a aptamer, is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.
    ARC186
  • HY-P1028A
    Hexa-D-arginine TFA

    Furin Inhibitor II TFA

    		 Bacterial Infection
    Hexa-D-arginine TFA (Furin Inhibitor II TFA) is a stable furin inhibitor with Ki values 106 nM, 580 nM and 13.2 μM for furin, PACE4 and prohormone convertase-1 (PC1), respectively. Hexa-D-arginine TFA blocks Pseudomonas exotoxin A and anthrax toxins toxicity in vitro and in vivo .
    Hexa-D-arginine TFA
  • HY-101832
    SBC-110736
    1 Publications Verification

    		 Ser/Thr Protease Metabolic Disease
    SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1, Figure 1.
    SBC-110736
  • HY-141724
    PCSK9 ligand 1

    		Ser/Thr Protease Cancer
    PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand. PCSK9 ligand 1 does not affect PCSK9 function .
    PCSK9 ligand 1
  • HY-120088A
    PF-06446846 hydrochloride
    1 Publications Verification

    		 Ser/Thr Protease Cardiovascular Disease
    PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34 .
    PF-06446846 hydrochloride
  • HY-120088
    PF-06446846

    		Ser/Thr Protease Cardiovascular Disease
    PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region .
    PF-06446846
  • HY-112598
    PF-06815345

    		Ser/Thr Protease Metabolic Disease
    PF-06815345 is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 significantly decreases the PCSK9 level in vivo in mouse .
    PF-06815345
  • HY-112598A
    PF-06815345 hydrochloride

    		Ser/Thr Protease Metabolic Disease
    PF-06815345 hydrochloride is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 hydrochloride significantly decreases the PCSK9 level in vivo in mouse .
    PF-06815345 hydrochloride
  • HY-P99050
    Sutimlimab

    		Complement System Cardiovascular Disease Inflammation/Immunology
    Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase .
    Sutimlimab
  • HY-148687
    SPC5001

    		Others Cardiovascular Disease
    SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .
    SPC5001
  • HY-148687A
    SPC5001 sodium

    		Others Cardiovascular Disease
    SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .
    SPC5001 sodium
  • HY-130245
    PCSK9 degrader 1

    		Ser/Thr Protease Metabolic Disease
    PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a Ki of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .
    PCSK9 degrader 1
  • HY-N10702
    PCSK9-IN-9

    		Ser/Thr Protease Cardiovascular Disease
    PCSK9-IN-9 is an isocoumarins of natural origin. PCSK9-IN-9 can inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), IDOL, and SREBP2 mRNA expression. PCSK9-IN-9 inhibits PCSK9 with an IC50 value of 11.9 μM .
    PCSK9-IN-9
  • HY-153785
    NH2-C6-ARC186 sodium

    		Complement System Inflammation/Immunology
    NH2-C6-ARC186 sodium is a modified ARC186 (HY-153098) with NH2-C6 that can be coupled to other peptides or molecules. ARC186 is a aptamer and a highly potent complement inhibitor that function by blocking the convertase-catalyzed activation of C5 .
    NH2-C6-ARC186 sodium
  • HY-128342
    Complement C5-IN-1

    		Complement System Inflammation/Immunology
    Complement C5-IN-1 (Compound 7) is a small-molecule inhibitor of complement component 5 protein (C5). Complement C5-IN-1 interacts with C5 to prevent its cleavage by the C5 convertase and blocks zymosan-induced the membrane-attack complex (MAC) deposition in 50% human whole blood with an IC50 of 0.77 µM .
    Complement C5-IN-1
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    1 Publications Verification

    REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)

    		 Ser/Thr Protease Cardiovascular Disease
    Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .
    Alirocumab (anti-PCSK9)
  • HY-P990091
    Riliprubart

    SAR 445088

    		 Complement System Inflammation/Immunology
    Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .
    Riliprubart
  • HY-P99965
    Crovalimab

    SKY59; RO7112689

    		 Complement System Cardiovascular Disease Metabolic Disease
    Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
    Crovalimab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: